Preclinical Research

 
News Articles for Preclinical Research top ^
2015/2/18
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, announced today potentially breakthrough findings from new preclinical research.
Sign-up for Aerie Pharmaceuticals Announces Potential Breakthroughs with New Preclinical Research investment picks
2015/2/23
Cardiovascular Systems, Inc. (CSI) (NASDAQ:CSII), today announced that CBSET, a not-for-profit preclinical research institute dedicated to biomedical research, education, and advancement of medical technologies, disclosed that modification of atherosclerotic plaque with CSI’s Diamondback 360 ® orbital atherectomy device improved paclitaxel absorption by 50 percent in calcified cadavaric peripheral arteries.
Sign-up for Modification of Atherosclerotic Plaque with Diamondback 360 Orbital Atherectomy Device Improved Drug Uptake in Peripheral Arteries in a Preclinical Study investment picks
2015/2/11
Bioanalytical Systems, Inc. (NASDAQ:BASI) today announced the addition of Srini Jayaraman,Ph.D. as Principal Investigator Discovery, and Braden M.
Sign-up for BASi Expands Scientific Expertise with the Hiring of Srini Jayaraman, Ph.D., Principal Investigator Discovery and Braden M. Kemmerling, D.V.M., Attending Veterinarian for Preclinical Services investment picks
2015/1/12
Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi therapeutics, today announced the presentation of new preclinical data on its Dicer substrate short interfering RNA (DsiRNA) therapeutics targeting MYC and β-catenin (CTNNB1) oncogenes in models of hepatocellular carcinoma (HCC) and colorectal cancer (CRC). The positive data, presented during a poster session on January 9 at MYC: From Biology to Therapy, a meeting of the American Association of Cancer Research (AACR) in La Jolla, Calif., provide additional insights into the parameters that impact the delivery and activity of DsiRNA therapeutics utilizing Dicerna’s proprietary EnCore™ lipid nanoparticle (LNP) technology in HCC and CRC tumor models.
Sign-up for Dicerna Pharmaceuticals Presents Positive Preclinical Data on its DsiRNA Therapeutics Targeting MYC and β-Catenin at AACR MYC: From Biology to Therapy Meeting investment picks
2015/1/28
http://www.marketwire.com/library/MwGo/2015/1/28/11G031610/Logo1-445926415.jpg http://www.marketwire.com/library/MwGo/2015/1/28/11G031610/Images/WHHLRabbitModel-405471649313.jpg WHHL Rabbit Model NEWARK, CA--(Marketwired - January 28, 2015) - CymaBay Therapeutics (NASDAQ: CBAY) today announced results from a preclinical study indicating the potential for MBX-8025 to decrease low-density lipoprotein cholesterol (LDL-C) in patients with homozygous familial hypercholesterolemia (HoFH). MBX-8025 is a potent and selective peroxisome proliferator-activated receptor delta (PPARδ) agonist that, in previous clinical studies, has been shown to reduce LDL-C in patients with mixed dyslipidemia.
Sign-up for CymaBay Therapeutics Announces Preclinical Data Demonstrating the Potential of MBX-8025 to Treat Homozygous Familial Hypercholesterolemia investment picks
2015/2/17
- Data highlights the use and potential of PEGPH20 to enhance the anti-cancer activity of monoclonal antibodies and NK cell access in breast and ovarian cancer preclinical models - SAN DIEGO , Feb.
Sign-up for Halozyme Announces Preclinical Study Results Of PEGPH20 Published In Molecular Cancer Therapeutics investment picks
2015/2/10
Optimized for Efficient Targeting to Multiple Key Muscle Tissues of Disease ORLANDO, Fla.
Sign-up for Amicus Therapeutics Presents Preclinical Data on Next-Generation Pompe ERT at WORLDSymposium(TM) 2015 investment picks
2014/12/8
-Potential Biomarkers of Response to CB-839 Identified in Myeloma Cells -Synergy of CB-839 With Pomalidomide Demonstrated in Multiple Myeloma Models SOUTH SAN FRANCISCO, Calif., Dec.
Sign-up for Calithera Presents Preclinical Study Findings for CB-839 at the 56th American Society of Hematology Annual Meeting investment picks
2014/12/3
SAN DIEGO AND TORONTO , Dec.
Sign-up for Aptose Biosciences to Present Preclinical Research Update for APTO-253 at the 56th American Society of Hematology Annual Meeting investment picks
2014/12/10
LAS VEGAS , Dec.
Sign-up for Preclinical Xenograft Studies Show Positive Results For Amooranin investment picks
2014/12/9
APTO-253 In Vivo Data Demonstrate Single-Agent and Combination Activity in AML SAN FRANCISCO, CA , Dec.
Sign-up for Aptose Biosciences Presents APTO-253 Preclinical Data at 56th American Society of Hematology Annual Meeting investment picks
2014/12/12
SAN DIEGO , Dec.
Sign-up for Halozyme Announces Presentations Of Preclinical Data At The San Antonio Breast Cancer Symposium Annual Meeting investment picks
2015/1/20
Early Phase Development Solutions Provides Dedicated Molecule Solution Teams including Scientific, Regulatory, and Project Management Experts to Accelerate Drug Development PRINCETON, N.J. , Jan.
Sign-up for Covance Launches New Solution to Bridge Preclinical to Clinical Development investment picks

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Preclinical Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Precision Manufacturing  |  Next: Preference Shares